152 related articles for article (PubMed ID: 34844493)
1. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2.
Di Fusco M; Moran MM; Cane A; Curcio D; Khan F; Malhotra D; Surinach A; Miles A; Swerdlow D; McLaughlin JM; Nguyen JL
J Med Econ; 2021; 24(1):1248-1260. PubMed ID: 34844493
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
3. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
[TBL] [Abstract][Full Text] [Related]
5. Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
Mues KE; Kirk B; Patel DA; Gelman A; Chavers LS; Talarico CA; Esposito DB; Martin D; Mansi J; Chen X; Gatto NM; Van de Velde N
Vaccine; 2022 Nov; 40(47):6730-6739. PubMed ID: 36163093
[TBL] [Abstract][Full Text] [Related]
6. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness.
Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Weng C
medRxiv; 2021 Oct; ():. PubMed ID: 34642696
[TBL] [Abstract][Full Text] [Related]
8. Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY.
; Green A; Curtis H; Hulme W; Williamson E; McDonald H; Bhaskaran K; Rentsch C; Schultze A; MacKenna B; Mahalingasivam V; Tomlinson L; Walker A; Fisher L; Massey J; Andrews C; Hopcroft L; Morton C; Croker R; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Hickman G; Ward T; Davy S; Mathur R; Tazare J; Eggo R; Wing K; Wong A; Forbes H; Bates C; Cockburn J; Parry J; Hester F; Harper S; Douglas I; Evans S; Smeeth L; Goldacre B
BMC Med; 2022 Jul; 20(1):243. PubMed ID: 35791013
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021.
Wang W; Kaelber DC; Xu R; Berger NA
JAMA Oncol; 2022 Jul; 8(7):1027-1034. PubMed ID: 35394485
[TBL] [Abstract][Full Text] [Related]
10. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
[TBL] [Abstract][Full Text] [Related]
11. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data.
Glatman-Freedman A; Bromberg M; Dichtiar R; Hershkovitz Y; Keinan-Boker L
EBioMedicine; 2021 Oct; 72():103574. PubMed ID: 34537449
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis.
Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Perl Y; Weng C
JMIR Public Health Surveill; 2022 May; 8(5):e35311. PubMed ID: 35486806
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 infections post-vaccination by HIV status in the United States.
Coburn SB; Humes E; Lang R; Stewart C; Hogan BC; Gebo KA; Napravnik S; Edwards JK; Browne LE; Park LS; Justice AC; Gordon K; Horberg MA; Certa JM; Watson E; Jefferson CR; Silverberg M; Skarbinski J; Leyden WA; Williams CF; Althoff KN;
medRxiv; 2021 Dec; ():. PubMed ID: 34909791
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research.
Wang L; Kaelber DC; Xu R; Berger NA
Blood Rev; 2022 Jul; 54():100931. PubMed ID: 35120771
[TBL] [Abstract][Full Text] [Related]
15. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative.
Song Q; Bates B; Shao YR; Hsu FC; Liu F; Madhira V; Mitra AK; Bergquist T; Kavuluru R; Li X; Sharafeldin N; Su J; Topaloglu U
J Clin Oncol; 2022 May; 40(13):1414-1427. PubMed ID: 35286152
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
[TBL] [Abstract][Full Text] [Related]
17. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.
Brosh-Nissimov T; Orenbuch-Harroch E; Chowers M; Elbaz M; Nesher L; Stein M; Maor Y; Cohen R; Hussein K; Weinberger M; Zimhony O; Chazan B; Najjar R; Zayyad H; Rahav G; Wiener-Well Y
Clin Microbiol Infect; 2021 Nov; 27(11):1652-1657. PubMed ID: 34245907
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study.
Ketkar A; Willey V; Glasser L; Dobie C; Wenziger C; Teng CC; Dube C; Hirpara S; Cunningham D; Verduzco-Gutierrez M
Adv Ther; 2024 Mar; 41(3):1075-1102. PubMed ID: 38216825
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
[TBL] [Abstract][Full Text] [Related]
20. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
